Neuren (NEU) – ASX Announcement 17 November 2026 Acadia enters exclusive distribution agreement for DAYBUE® STIX in Japan Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU)’s exclusive global partner for trofinetide, Acadia Pharmaceuticals (Nasdaq: ACAD), has announced that it has entered...
Acadia enters DAYBUE STIX distribution agreement in Japan
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Neuren is entitled to receive significant milestone payments and royalties under its licensing agreement with Acadia. The announcement highlights Neuren's ongoing collaboration with Acadia and the potential for future product launches in Japan.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Final Director's Interest Notice - P. Davies
- Initial Director's Interest Notice - Zita Peach
- Zita Peach to succeed Patrick Davies as Board Chair
- Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded
- FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals